Associated Papers
Pharmacokinetic recall study of Estonian Biobank participants with novel genetic variants in CYP2C19 and CYP2D6.
Krebs K et al.
Npj Genomic Medicine, 2026
Natural Polymorphic Variants in the CYP450 Superfamily: A Review of Potential Structural Mechanisms and Functional Consequences.
Prost R et al.
International Journal of Molecular Sciences, 2025
The pharmacogenomic landscape in the Chinese: An analytics of pharmacogenetic variants in 206,640 individuals.
Wang LY et al.
Innovation (cambridge (mass.)), 2025
In vitro assessment of the impact of 30 CYP2C19 variants on citalopram metabolism.
Wang P et al.
Peerj, 2025
Functional evaluation of CYP2C19 and CYP3A4 gene polymorphism on ibuprofen metabolism.
Yuan LJ et al.
Toxicology and Applied Pharmacology, 2023
The genetic landscape of major drug metabolizing cytochrome P450 genes-an updated analysis of population-scale sequencing data.
Zhou Y et al.
The Pharmacogenomics Journal, 2022
Effects of 31 recombinant CYP2C19 variants on clomipramine metabolism in vitro.
Lan T et al.
Journal of Psychopharmacology (oxford, England), 2021
CYP2C9 and CYP2C19: Deep Mutational Scanning and Functional Characterization of Genomic Missense Variants.
Zhang L et al.
Clinical and Translational Science, 2020
Functional characterization of CYP2C19 variants in nebivolol 4-hydroxlation in vitro.
Zhou XY et al.
Drug Testing and Analysis, 2018
Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular Medicine.
Brown SA et al.
Journal of Personalized Medicine, 2018
The effects of cytochrome P450 2C19 polymorphism on the metabolism of voriconazole in vitro.
Xu RA et al.
Infection and Drug Resistance, 2018
Molecular dynamics investigations of membrane-bound CYP2C19 polymorphisms reveal distinct mechanisms for peripheral variants by long-range effects on the enzymatic activity.
Cui YL et al.
Molecular Biosystems, 2017
Effects of CYP2C19 variants on methadone metabolism in vitro.
Lan T et al.
Drug Testing and Analysis, 2017
Assessing the capability of massively parallel sequencing for opportunistic pharmacogenetic screening.
Ng D et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics, 2017
Targeted Next-Generation Sequencing for Comprehensive Genetic Profiling of Pharmacogenes.
Han SM et al.
Clinical Pharmacology and Therapeutics, 2017
Effects of CYP2C19 Variants on Fluoxetine Metabolism in vitro.
Fang P et al.
Pharmacology, 2017
Genetic polymorphisms and phenotypic analysis of drug-metabolizing enzyme CYP2C19 in a Li Chinese population.
Ding Y et al.
International Journal of Clinical and Experimental Pathology, 2015
Recent advances in the pharmacogenetics of clopidogrel.
Cuisset T et al.
Human Genetics, 2012
Molecular mechanisms of genetic variation and transcriptional regulation of CYP2C19.
Helsby NA et al.
Frontiers in Genetics, 2012
Evaluation of the effects of 18 non-synonymous single-nucleotide polymorphisms of CYP450 2C19 on in vitro drug inhibition potential by a fluorescence-based high-throughput assay.
Wang H et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2011
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
Wang H et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2011
Genetic variations and haplotypes of CYP2C19 in a Japanese population.
Fukushima-Uesaka H et al.
Drug Metabolism and Pharmacokinetics, 2005
Patient-derived glioblastoma organoids reflect tumor heterogeneity and treatment sensitivity.
Verduin M et al.
Neuro-oncology Advances, 0